FIH Study to Evaluate the Tolerability of PF-07832837
Phase 1
119
about 2.6 years
18–70
3 sites in CA, FL, PA
About this study
This trial is testing a treatment called PF-07832837 in healthy adults and people with atopic dermatitis. The goal is to see if this treatment is safe and how it works in the body.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take PF-07832837
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants With Treatment Emergent Treatment-Related AEs and SAEs Following multiple ascending doses (MAD), Number of Participants With Treatment Emergent Treatment-Related AEs and SAEs in participants with atopic dermatitis (AD), Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and serious adverse events (SAEs) Following single ascending doses (SAD), Number of Participants with Change from Baseline in Electrocardiogram (ECG) Findings Following MAD, Number of Participants with Change from Baseline in Electrocardiogram (ECG) Findings Following SAD, Number of Participants with Clinically Significant Change from Baseline in Cardiac Telemetry Findings Following SAD, Number of Participants with Clinically Significant Change from Baseline in Vital Signs Following SAD, Number of Participants with Clinically Significant Change from Baseline in Vital Signs in participants with AD
Secondary: Maximum Observed Serum Concentration (Cmax) of PF-07832837 following MAD, Maximum Observed Serum Concentration (Cmax) of PF-07832837 following SAD, Percent change from baseline in Eczema Area and Severity Index (EASI) total score at Week 8, Terminal serum elimination half life (t1/2) of PF-07832837 following SAD, Time to Reach Maximum Observed Serum Concentration (Tmax) of PF-07832837 following MAD, Time to Reach Maximum Observed Serum Concentration (Tmax) of PF-07832837 following SAD
Dermatology